A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Sponsor:
- Arcus Biosciences
- Sponsor Study ID:
- PEAK-1
- CTO #:
- 104243
- NCT Number:
- NCT07011719
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Kidney
- Study Objectives:
- To compare PFS of casdatifan + cabozantinib versus placebo + cabozantinib in all randomized patients.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Ho, Thai, at hothai@musc.edu .
- Study Coordinator, Tucker, Renee, at tuckerr@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina